© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
FDA Clears First Biosimilar to Lucentis
September 20, 2021
The drug won't be available till next year but is expected to dent sales of Roche's blockbuster for age-related macular degeneration and other eye diseases.
Challenges in Biosimilar Acceptance, per Savitha Vivian of OptumRx
September 12, 2021
Senior Vice President of OptumRx, Savitha Vivian, shares with MHE when expected upcoming biosimilars are coming to market and the challenges she's seeing with biosimilar acceptance.
Optum Rx Executive: Biosimilars Have Momentum But It Will Take the Approval of Humira, Other Commonly Prescribed Biologics for Them to Really Take Off
September 11, 2021
In an interview with MHE, SVP Savitha Vivian said the biosimilars to Humira and Novolog that are expected to be on the market in the next few years could have the kind of impact that proponents of biosimilars have been hoping for.
Rituximab Biosimilars Produce Big Cost Savings, are Effective
September 07, 2021
A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43 percent reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.
David Calabrese of OptumRx Talks Biden's Interest of More Biosimilars in Market
August 16, 2021
In this second part of a two-part video series, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.
Ophthalmologist Group Wants U.S. Government to Push Back Against Avastin Biosimilars
August 09, 2021
The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the eye.
Biosimilar and Interchangeable Semglee Insulin Could Save U.S. Healthcare Hundreds of Millions
August 06, 2021
FDA approval means that pharmacists can swap biosimilar Semglee, an insulin product, for brand-name Lantus, although state-level pharmacy rules may apply.
An FDA First: Semglee Is Approved As An Interchangeable Biosimilar
July 29, 2021
FDA approval means that pharmacists can swap biosimilar Semglee, an insulin product, for brand-name Lantus, although state-level pharmacy rules may apply.
Vizient’s Outlook Report Is a Mixed Bag: Projected 2022 Drug Spend, White Bagging, Insulin Competition and COVID-19 Treatment. It’s All in There.
July 29, 2021
Wide ranging report covers a lot of ground. It sounds an optimistic note about biosimilars but is critical of white bagging.
The Generic, Biosimilar Medicine Industry Today and What it Can Become in The Next Decade
July 14, 2021
International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.